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J. A. Eldred, L. J. Dawes and I. M. Wormstone*
School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
Fibrosis affects multiple organs and is associated with hyperproliferation, cell transdifferentiation,
matrix modification and contraction. It is therefore essential to discover the key drivers of fibrotic
events, which in turn will facilitate the development of appropriate therapeutic strategies. The
lens is an elegant experimental model to study the processes that give rise to fibrosis. The molecular
and cellular organization of the lens is well defined and consequently modifications associated with
fibrosis can be clearly assessed. Moreover, the avascular and non-innervated properties of the lens
allow effective in vitro studies to be employed that complement in vivo systems and relate to clinical
data. Using the lens as a model for fibrosis has direct relevance to millions affected by lens disorders,
but also serves as a valuable experimental tool to understand fibrosis per se.
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Fibrosis is defined as ‘a pathological condition in
which tissue structure is disrupted by production of
excessive extracellular matrix (ECM)’ [1,2]. Fibrosis
is a chronic multiple organ disorder with some cases
having a worse survival rate than cancer [3], and it
has been suggested that fibrosing conditions are
responsible for almost half of all known deaths [4].
In association with enhanced matrix production,
typical features of tissue fibrosis include hyperproli-
feration, transdifferentiation of both epithelial cells
and fibroblasts to myofibroblasts and matrix contrac-
tion. The generation of myofibroblasts has long been
assumed to be pivotal for the initiation of fibrotic
tissue formation and establishment of a pro-contractile
apparatus, which leads to matrix contraction.
Recently, work carried out on lung and lens cells has
begun to question the established dogma and suggest
that rather than be profibrogenic, myofibroblasts may
in fact play a protective role to regulate the degree of
fibrotic response [5–7]. Elucidating the role of myofi-
broblasts and the signalling mechanisms that drive
specific fibrotic events is essential in the quest to
develop effective strategies to treat fibrotic disorders.
To achieve this, appropriate models need to be
employed and the value of the lens should not be
underestimated as a model of fibrosis.2. THE LENS: A MODEL FOR FIBROSIS
The lens is an exquisite biological tool to investigate a
host of mechanisms involved in tissue fibrosis. To
appreciate the benefits the lens offers it is important
to understand the organization and features of ther for correspondence (i.m.wormstone@uea.ac.uk).
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1301normal lens (figure 1a) [8]. The adult lens is isolated
from other tissues and has no innervations or vascular
system, receiving all required nutrients from the aqu-
eous and vitreous humours that bathe it. The lens
can be separated into distinct cellular groups. Cells
within the central anterior epithelium have been
present since lens vesicle formation during embryo-
genesis. Moreover, both cell death and division is
negligible in this population. However, the cells in
the peripheral epithelium are capable of migration,
cell division and differentiation into lens fibre cells
that form the bulk of the lens. In association with
these cellular compartments markers can be used to
define cell phenotype. For example, the forkhead tran-
scription factor FOXE3 is expressed in the lens
epithelium [9], along with PAX6, the eye master
gene [10], whereas b-crystallin can serve as an early
differentiation marker, while g-crystallin and major
intrinsic protein (MIP) are markers of a mature fibre
cell [11]. In the normal lens order is maintained, but
circumstances can arise that lead to disruption of
lens integrity and provoke a fibrotic change. The abil-
ity to monitor changes within a well-defined system is
critical to understand the nature of both the induction
of a wound healing response and fibrotic changes.
Models available to study fibrosis such as cell lines
[12], transgenic models [13,14] and tissue culture
[15–17] are well characterized in the lens. Post-
mortem analysis and clinical data also greatly aid the
understanding of fibrosis in the lens [17–19]; this
information may not strictly inform us of the causal
factors, but importantly the data do serve as a blue-
print of changes that are seen in patients. This
fundamental information of clinical disorders should
direct researchers to ensure whichever experimental
system is employed has relevance to changes seen in
patients. If the model adopted is appropriate then
mechanisms giving rise to that change can be
determined and advance our knowledge. FibroticThis journal is q 2011 The Royal Society
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Figure 1. (a) A schematic illustrating the cellular organization
of the human lens. The site of anterior subcapsular cataract
(ASC) is depicted in (b); ASC is associated with modification
to the epithelium that is clinically seen as a fibrotic plaque (c;
image kindly supplied by Dr Hong Zhang, Harbin Medical
University, China). Grey area, capsule; purple area, epithelial
cells; red area, germinative cells; orange area, elongating
fibres; dark yellow area, cortical fibres and light yellow area,
nucleus.
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Figure 2. The effect of TGFb on lens transparency and mor-
phology. Whole lenses were cultured for 5 days (a,c) without
TGFb or (b,d) with TGFb2. (a,b) Lenses were photo-
graphed through the posterior pole. (c,d) Sagittal sections
were stained with haematoxylin and eosin; the equator of
the lens is at the bottom edge of the micrograph in each
case. In the presence of TGFb, lenses developed anterior
opacities (b) that corresponded with cellular plaques (d,
arrowhead) underlying the lens capsule (ca). (a) Without
TGFb lenses remained clear and (c) retained normal histology
with a monolayer of epithelial cells (ep) covered by the lens
capsule overlying the fibre mass (fm). At the lens equator
(arrow), cells began to elongate and to differentiate into
fibres. Scale bars, (a,b) 400mm; (c,d) 250mm. Previously
published in Hales et al. [28] with permission from the copy-
right holder, the Association for Research in Vision and
1302 J. A. Eldred et al. Review. The lens as a model for fibrotic disease
 on March 14, 2011rstb.royalsocietypublishing.orgDownloaded from disorders of the lens affect millions of people [20,21],
and for the purpose of this review the two best
characterized conditions, anterior subcapsular cataract
(ASC) and posterior capsule opacification (PCO), will
be discussed.Ophthalmology (ARVO).(a) Anterior subcapsular cataract
ASC is characterized by dense light scattering fibrotic
regions underneath the anterior capsule (figure 1).
ASC is the least prevalent form of cataract in the UK
with a prevalence of 2–3% [20,22], although ASC is
more prevalent in eastern societies such as Japan and
Singapore [20,23]. The occurrence of ASC is asso-
ciated with several conditions that involve ocular
trauma, such as impact injury, inflammation or irri-
tation of the eye, such as atopic dermatitis [24–26].
In recent years both analysis of human anterior sub-
capsular material [23,25] and animal model studies
[15,27] have been conducted to determine the mol-
ecular and cellular mechanisms that underpin ASC
formation. Marcantonio et al. [25] performed a cyto-
chemical analysis of four ex vivo human ASCs. In
this study folding and thickening of the anterior lens
capsules was observed, with cells in these regions
exhibiting a typical myofibroblast morphology, i.e.
spindle-shaped, elongated and exhibiting positive
staining for alpha smooth muscle actin (aSMA).Phil. Trans. R. Soc. B (2011)A previous investigation by Lee & Joo [23] revealed
that transdifferentiation of lens epithelial cells in
ASC causes the production of large amounts of
ECM proteins such as collagen I, III and fibronectin,
which are not normally present in the lens capsule.
The excessive production and deposition of ECM is
a general characteristic of fibrosis [1]. Work initially
using isolated whole rat lens cultures demonstrated
that the fibrotic changes described above could be
mimicked following transforming growth factor b
(TGFb) exposure (figure 2) [15]. Consequently, as
with many fibrotic disorders, TGFb has become the
major area of study.(b) Posterior capsule opacification
PCO is the most common fibrotic condition in the lens
that develops following cataract surgery [21]. At pre-
sent, the only means of treating cataract is by
surgical intervention, and this initially restores high
Intraocular Lens
anterior capsule
residual lens cells
supporting loops
(haptics) posterior capsule
capsular wrinkling
intraocular lens
(a)
(b)
(c)
Figure 3. Schematics of (a) the post-surgical capsular bag and (b) the extensive growth and modification that gives rise to
posterior capsule opacification following cataract surgery. (c) A dark-field micrograph of a capsular bag removed from a
donor eye that had undergone cataract surgery prior to death that exhibits light scattering regions beneath an intraocular
lens. First published in Wormstone [29] with permission from Experimental Eye Research (Elsevier).
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nificant proportion of patients to such an extent that
a secondary loss of vision occurs (figure 3).
A modern cataract operation generates a capsular
bag, which comprises a proportion of the anterior
and the entire posterior capsule [21]. The bag remains
in situ and partitions the aqueous and vitreous
humours, and in the majority of cases, houses an intra-
ocular lens. The production of a capsular bag
following surgery permits a free passage of light
along the visual axis through the transparent intra-
ocular lens and thin acellular posterior capsule.
However, on the remaining anterior capsule, lens
epithelial cells stubbornly reside despite enduring the
rigours of surgical trauma. This resilient group of
cells then begin to re-colonize the denuded regions
of the anterior capsule, encroach onto the intraocular
lens surface, occupy regions of the outer anterior cap-
sule and most importantly begin to colonize the
previously cell-free posterior capsule. Cells continue
to divide and cover the posterior capsule and canPhil. Trans. R. Soc. B (2011)ultimately encroach on the visual axis. A thin cover
of cells is insufficient to affect the light path, but sub-
sequent changes to the matrix and cell organization
can give rise to light scatter.
PCO is a classical fibrotic disease exhibiting hyper-
proliferation in response to injury, myofibroblast
formation, matrix deposition and contraction [21]. A
large complement of methods is available to study
PCO; cell lines provide an abundant and reliable
source of material to investigate the relationship
between signalling pathways and functional effects
including cell growth, transdifferentiation, matrix
deposition and contraction [5,12,30,31]. Tissue cul-
ture models have also served the research field well,
and include lens explants [16] and in vitro capsular
bag models [17,32–34]. The latter employ a sham
cataract operation to produce a capsular bag. These
systems have the same cellular organization as in vivo
and cells grow on their natural matrix. Moreover,
lens cells within these tissue culture systems can be
maintained in serum-free medium (without
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The culture conditions can therefore be carefully con-
trolled and thus interpretation of the data is easier than
in more complex systems. In addition to these in vitro
methods, in vivo animal models have been developed
[35–37] and it is probable that transgenic animals
will be studied further to determine PCO progression.
A number of features are common to both ASC and
PCO, and not surprisingly TGFb is again strongly
implicated [21]. Histological analysis of post-mortem
specimens demonstrates increased matrix deposition,
cell transdifferentiation and matrix contraction; more-
over, activated TGFb signalling molecules, Smads, are
present. Moreover, application of TGFb to in vitro
capsular bags, lens epithelial explants or cell lines
induces myofibroblast expression, increased matrix
production and matrix contraction, thus mimicking
the clinically observed features. Consequently, TGFb
again serves as a major focus of research in PCO for-
mation; however a number of other mechanisms are
also likely to govern fibrosis and it is important to
establish a full picture in our assessment of fibrotic
tissue formation.3. REGULATION OF FIBROSIS
A number of cellular and biological processes contrib-
ute to fibrotic conditions and it is important to
consider the mechanisms underpinning their involve-
ment; these include how inflammation can drive the
fibrotic process and the factors that lead to increased
matrix production/deposition and modification that
ultimately define fibrotic conditions in the lens and
throughout the body.4. INFLAMMATION
Inflammation has long been regarded as ‘setting the
stage’ for fibrosis development. Inflammatory response
components and angiogenic factors are frequently pre-
sent in numerous fibrotic disorders; however the
essential mechanistic controls involved are poorly
understood. Tissue damage or injury including
surgery results in inflammation with the aim of repair-
ing and protecting the surrounding tissues. Damaged
tissues release chemicals that attract white blood cells
such as the lymphocyte T helper cells that help coordi-
nate the ensuing immune response by releasing
cytokines such as interleukins. These secreted proteins
activate resident macrophages that further enhance the
production of cytokines, chemokines and other inflam-
matory mediators as well as recruiting monocytes [38],
with the intention of returning injured tissue back to
normal status.
The concentration of several interleukin isoforms
along with monocyte chemoattractant protein-1
(MCP-1) and interferon gamma (IFN-g) have been
shown to increase in the aqueous humour of patients
experiencing idiopathic anterior uveitus (inflammation
of the iris and ciliary structures of the uvea) [39].
A number of people exhibit chronic inflammation of
the eye (uveitis) which results in elevated levels of cyto-
kines in the ocular fluids. Uveitis is relatively common
and is the fifth leading cause of blindness in EuropePhil. Trans. R. Soc. B (2011)[40]. Interestingly, 40 per cent of uveitis patients
develop cataracts including a high level of anterior
subcapsular opacities [24,41]. Moreover, sustained
inflammatory responses are likely to exacerbate the
rate of PCO progression. Consequently, gaining an
understanding of the defined role inflammation plays
in fibrosis is vital.
The lymphocyte T-helper cells upregulated during
inflammatory episodes have two variations. The Th1-
type produce cytokines and chemokines, such as
interleukins (IL)-2, IL-12, IFN-g and tumour necrosis
factor (TNF)-a, which in general facilitate tissue res-
toration [42]. IFN-g can decrease cell proliferation
along with reducing collagen synthesis and deposition
and attenuates expression of pro-fibrotic cytokines
[43]. Th1-type cytokines and chemokines also stimu-
late resident M1 macrophages that subsequently
yield reactive oxygen species (ROS) and IL-1b [42].
IL-1b facilitates cells to synthesize matrix metalloprotei-
nases (MMPs), and prostaglandin E2 that prevents
proliferation and collagen production. Furthermore,
M1macrophages generate TNF-a, an effective inhibitor
of type 1 collagen [44].
In contrast, Th2-type lymphocytes increase
expression of factors that encourage fibroblast expan-
sion and deposition of matrix, and thus augment
fibrosis. For example, Th2-type cells induce IL-4, a
stimulant of proliferation and inducer of both types I
and III collagen and fibronectin [45]. IL-4 additionally
heightens the production of TGFb and connective
tissue growth factor [46] and decreases IFN-g.
Secretion of IL-5 from Th2-type cells stimulate B
cell growth and activates eosinophils which likewise
produce the pro-fibrotic ligands TGFb and PDGF
and hence enhance fibroblast proliferation. Eosino-
phils are also reported to accumulate in the lesions
of various fibrotic disorders [47]. Like IL-4 the Th2
specific IL-13 stimulates TGFb formation and can
directly activate fibroblasts [48]. Th2-type cells also
initiate M2 macrophages to release PDGF and IL-10
(a pro-inflammatory interleukin that decreases IFN-g
and TNF-a). Class M2 macrophages also secrete
TGFb and inhibitors to MMPs, impairing routine
ECM remodelling [49].
The correlation of inflammation with fibrosis has
been targeted for innovative therapies directed at
ocular fibrotic disorders, such as the treatment of
PCO with anti-inflammatory drugs [50]. However,
this approach has demonstrated little benefit in
preventing fibrosis; this could be due to anti-
inflammatory therapies affecting both advantageous
Th1-type cells and the potentially damaging Th2
cells, in addition to diminishing prostaglandin E2
responses which permits increases to collagen
synthesis [42]. Importantly, Laurell & Zetterstrom
[50] found that anti-inflammatory treatment of
patients undergoing cataract removal surgery resulted
in a higher number of patients developing fibrotic
PCO 4 years post-surgery than in subjects treated
with a placebo. Moreover, Symonds et al. [51] demon-
strated that the steroid dexamethasone, which is
routinely administered to patients undergoing cataract
surgery, improves cell survival and increase collagen
type I synthesis in a rat lens explant model of PCO.
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tible to the actions of anti-inflammatory molecules.
Chandler et al. [52] tested the direct actions of
cyclooxygenase 2 (COX-2) through application of
rofecoxib or celecoxib to canine capsular bags; both
COX-2 inhibitors suppressed PCO.
It therefore appears that when considering methods
to manage inflammation at the site of injury, maintain-
ing homeostasis of specific subsets of lymphocytes
must be tightly controlled; an imbalance can have det-
rimental effects on ECM production (Th2) and loss
(Th1). Moreover the actions of anti-inflammatory
drugs on cell behaviour, within the affected tissue,
and the ability of these cells to locally synthesize and
respond to inflammatory cytokines should also be
considered.
A number of cytokines become elevated at the site
of injury. These can drive hyperproliferation or med-
iate matrix deposition, transdifferentiation or matrix
contraction. Growth factors such as fibroblast growth
factor (FGF), epidermal growth factor and platelet-
derived growth factor (PDGF) can promote growth
[12,31,53], but the growth factor most commonly
associated with the fibrotic changes is TGFb [1].
During inflammation of the eye, TGFb is believed to
suppress the actions of white blood cells and thus control
the degree of inflammatory response [54]. While this
role is of benefit to the eye, active TGFb becomes avail-
able to responsive cells and in such cases can drive
fibrosis in these tissues. Understanding the role of
TGFb in fibrosis is therefore critical if we are to advance
our knowledge and apply this to future strategies.5. TGFb: THE ORCHESTRATOR OF FIBROSIS
The cytokine TGFb is widely implicated as being a
central mediator of the fibrotic response [1]; conse-
quently, there is a great deal of interest regarding the
role of TGFb in fibrotic disorders of the lens,
namely ASC and PCO.
TGFb is present in the aqueous humour of the eye
and exists largely in a latent, inactive form [55,56].
Under normal conditions TGFb activity is tightly
regulated by proteins in the ocular humours such as
a2-macroglobulin, which have a high affinity for free
active TGFb [57], however following trauma to the
lens, e.g. by surgical injury, active levels of TGFb
can be elevated. Following trauma, a wound healing
response is initiated that causes an induction of
TGFb activators such as plasmin proteases MMP-2
and -9 [58] and thrombospondin-1 [59], which
cleave latent TGFb precursor via degradation of pro-
segments. Moreover, increased levels of ROS have
also been reported to promote TGFb activity
[60,61]. The induction of TGFb following cutaneous
injury is a common repair response; however, the sus-
tained activation of TGFb during this process has
implicated this protein as being a predominant
initiator of the fibrotic response in vivo. In human
post-burn hypertrophic scars [62] and in dermal fibro-
tic lesions of scleroderma patients, expression of
TGFb isoforms and TGFb receptors are elevated
[63]. Similarly, with respect to the lens, capsular bag
tissue from donor eyes that had undergone cataractPhil. Trans. R. Soc. B (2011)surgery has identified all three TGFb isoforms and
receptors [64] and elevated levels of active TGFb2
[17]. TGFb2 is the major isoform in the eye, however
TGFb1 and 3 can be activated following surgical
injury, such as cataract surgery, where breaching of
the blood aqueous barrier initiates an inflammatory
response [55].
Much evidence confirms that following trauma to
the lens, active levels of TGFb can induce the cellular
responses key to fibrosis, namely: epithelial to
mesenchymal transdifferentiation; increased ECM
production and deposition and matrix contraction
[1,21,65]. One of the major effects of TGFb on lens
epithelial cells is to promote transdifferentiation to a
myofibroblast phenotoype. Analysis of human ASC
tissue has revealed elevated levels of the myofibroblast
markers aSMA and fibronectin [23]. Moreover,
TGFb has been shown to induce ASC in a rat lens
culture model (figure 3) [15].
With respect to understanding the role of TGFb in
PCO, the post-mortem analysis of a capsular bag
received from a donor 1 month following cataract
surgery revealed increased levels of TGFb-induced
fibrotic markers including the transdifferentiation
marker aSMA and matrix contraction/wrinkling of
the posterior capsule (figure 4) [17]. These changes
were replicated by application of TGFb to in vitro
human capsular bags (figure 5). TGFb-induced trans-
differentiation has long been assumed to be critical for
inducing the synthesis and contraction of the ECM
[66]. Contraction of the ECM of the lens capsule
causes the formation of wrinkles which induce light
scatter and with increasing severity can lead to visual
loss. It is therefore of great importance to understand
the cellular mechanisms that regulate TGFb-induced
matrix contraction in fibrotic conditions such as
PCO in order to provide potential targets for inhi-
bition by pharmaceutical agents. To permit thorough
investigations of the signalling pathways driving fibro-
tic events, human lens cell lines have been employed.
Using this biological tool, specific assays have been
developed to assess matrix production, trans-
differentiation and matrix contraction (figures 6 and
7) [5,12,30]. Inhibition studies could then be
employed to tease out the pathways mediating
TGFb-induced fibrosis. Using this approach, Dawes
et al. [5] tested the relationship between transdifferen-
tiation of human lens epithelial cells and matrix
contraction. In contrast to conventional wisdom, it
was revealed that aSMA expression and fibronectin/
fibronectin receptors are not critical to TGFb-induced
matrix contraction (figure 8). The aforementioned
study raises provocative questions that concern the
importance of TGFb-mediated transdifferentiation in
regulating matrix contraction in non-lenticular fibrotic
pathologies (figure 9). In the case of lens fibrosis it
cannot be assumed that transdifferentiation is a
redundant process in regulating fibrotic events as
myofibroblasts are commonly regarded as key
mediators of increased ECM production and depo-
sition, a key characteristic of ASC and PCO [21,65]
and a common feature of fibrotic pathologies [1].
However, work in lung cells suggests a reduction in
aSMA expression can promote matrix deposition. It
(a) (b)
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AC
PC
500 µm
500 µm 100 µm
100 µm
100 µm
(c) (d)
(e) ( f )
Figure 4. Examination of a capsular bag removed from a donor eye that had undergone cataract surgery 32 days before the time
of death. (a) A phase-contrast micrograph shows wrinkling of the posterior capsule and the associated cellular morphology.
(b) Fluorescence micrograph illustrating several layers of nuclei, some of which exhibit a spindle-shape (arrows) and are
oriented along capsular wrinkles. (c) Fluorescence micrograph showing F-actin distribution in cells growing across the pos-
terior capsule (PC) and also those growing on the outer surface of the anterior capsule (AC). (d) A higher-magnification
fluorescent micrograph demonstrating the F-actin organization of cells residing on the posterior capsule in association with
matrix contraction. (e) Fluorescence micrograph showing aSMA distribution in cells growing across the posterior capsule
and also those growing on the outer surface of the anterior capsule. ( f ) A higher-magnification fluorescence micrograph
demonstrating the aSMA organization of cells residing on the posterior capsule in association with matrix contraction.
Previously published in Wormstone et al. [17] with permission from the copyright holder, the Association for Research
in Vision and Ophthalmology (ARVO).
1306 J. A. Eldred et al. Review. The lens as a model for fibrotic disease
 on March 14, 2011rstb.royalsocietypublishing.orgDownloaded from would therefore appear that the relationship between
matrix production deposition and myofibroblast invol-
vement needs further investigation in a number of
tissues to determine whether a consensus pattern is
present or not.
To understand the development of fibrotic pathol-
ogies it is of fundamental importance to ascertain the
mechanisms by which TGFb signals mediate the cel-
lular events of transdifferentiation, matrix contraction
and ECM synthesis. A body of evidence has been
obtained in recent years concerning TGFb signal
transduction pathways (for comprehensive reviews on
TGFb signalling see references [67,68]). The major
intracellular signalling system identified for TGFb is
through translocation of Smad proteins. TGFb
initiates its response through a complex of high-affinity
cell surface receptors consisting of two type I and two
type II transmembrane serine/threonine kinasePhil. Trans. R. Soc. B (2011)receptors [69]. TGFb ligand binding links the consti-
tutively active type II receptor kinases to the dormant
type I receptor kinases, allowing the type II receptor
to phosphorylate the cytoplasmic domain of the
type I. The activated type I receptor recruits and
phosphorylates receptor regulated Smads (R-Smads)
at their C-terminus enabling them to complex
with the common-mediator (Co) Smad Smad4. The
R-Smads Smad2 and Smad3 are commonly associated
with mediating TGFb signals [68], although recen-
tly TGFb-induced phosphorylation of R-Smad1/5,
associated with bone morphogenetic protein, has
been demonstrated in non-ocular epithelial cells
[70]. The R-Smad/Smad4 heteromeric complex is
free to translocate from the cell cytoplasm to the
nucleus and is competent to associate with transcrip-
tional co-activators and co-repressors to direct
specific transcriptional responses [68]. R-Smad
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Figure 5. Replication of clinical features of lens fibrosis in a human in vitro tissue culture model for posterior capsule opacifica-
tion. (a,b) Phase-contrast and (d,e) fluorescent micrographs demonstrate enhance matrix contraction and aSMA expression in
response to TGFb (10 ngml21) exposure (b,e). These images can be converted to a binary form that permits quantification
(c, f ), which greatly aids comparative assessment. Data were previously published by Wormstone et al. [33] with permission
from Experimental Eye Research (Elsevier).
(a)
(b)
Figure 6. A gene expression profile of selected matrix components in the human lens cell line FHL 124. (a) The baseline signal
of matrix component gene expression detected in non-stimulated serum-free controls using oligonucleotide microarrays.
(b) Changes detected in gene expression of matrix components following 24 h culture in TGFb (10 ngml21) conditions
using oligonucleotide microarrays. The data are presented in a colorimetric form to indicate level detected (a) and fold
change (b). A key for each is provided. Data previously published by Dawes et al. [30] with permission from Molecular Vision.
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pendently of Smad4 binding in both lenticular and
non-lenticular cell types [6,71,72]. TGFb can termi-
nate the induction of its own target genes by
recruiting Smad7, which negatively regulates signall-
ing strength and duration, through formation of a
negative-feedback loop [73].
A body of evidence has been obtained regarding the
involvement of the classical TGFb/Smad signalling
pathway in the pathogenesis of fibrotic disorders of
the lens [6,13,14,19]. Work by Saika et al. [19] has
shown Smad3 and Smad4 to be present in cell nuclei
of post-operative human lenses and in injury-induced
epithelial to mesenchymal transition (EMT) murine
lenses [74], therefore implicating activation by TGFbPhil. Trans. R. Soc. B (2011)following trauma. The activation of Smad3/4 by
endogenous TGFb was confirmed in injury-induced
fibrosis of murine lenses where the application of
TGFb neutralizing antibodies prior to lens injury
inhibited the translocation of Smad3/4 to lens cell
nuclei [74]. Smad3 rather than Smad2 dependent sig-
nalling is widely implicated in fibrotic conditions
throughout the body [75]; for example, elevated
levels of activated Smad3 have been detected in
models of bleomycin-induced fibrosis, hepatic stellate
cell (HSC) activation and the leading edge of sclero-
derma lesions [76–78]. Therefore, in more recent
years Smad3 knockout transgenic models have been
employed to elucidate the importance of TGFb/
Smad3-dependent pathway in regulating the cellular
no TGFb
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Figure 7. Validation of an in vitro method, the patch assay, to assess matrix contraction by human lens epithelial cells.
The images clearly show the appearance of cell-free regions within the patch area after 3 days of exposure to 10 ngml21
TGFb1 or -b2, which was determined by Coomassie blue staining. Moreover, these cell-free regions did not exhibit positive
PAS staining or collagen, thus indicating matrix movement in association with cells. Data previously published by Dawes et al.
[5] with permission from the copyright holder, the Association for Research in Vision and Ophthalmology (ARVO).
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throughout the body [76]. A key focus of research in
the context of lens fibrosis has been the role of
Smad3 signalling in the process of EMT. In particular,
Saika et al. [14] observed that both TGFb2-induced
and injury-induced EMT and aSMA expression were
inhibited in the lens epithelium of Smad3 knockout
mice. Furthermore, Banh et al. [13] observed aSMA
expression in a TGFb1/Smad3 knockout mouse,
although the level of aSMA expression was reduced
compared to wild-type lenses. Loss of Smad3 in
mice also reduces the expression of type I collagen fol-
lowing trauma to the lens [14]. The reduction in
TGFb-induced fibrosis, detected by EMT and col-
lagen I synthesis, in Smad3 knockout mice is not
exclusive to the lens as these models show reduced
scarring of the skin following irradiation [75], protec-
tion from renal tubulointerstitial fibrosis [79] and are
resistant to bleomycin-induced pulmonary fibrosis
[80]. Concurrent with the aforementioned studies,
Dawes et al. [6] detected a significant reduction in
expression of TGFb-induced fibrotic markers aSMA
and fibronectin in a Smad4 knockdown human lens
epithelial cell line, therefore suggesting TGFb
Smad3/Smad4 signalling may regulate transdif-
ferentiation of human lens epithelial cells. Most
interestingly, this study found TGFb-induced matrix
contraction and Smad7 expression to be independent
of Smad4 expression, suggesting that TGFb/Smad
independent pathways may also regulate lens fibrosis.Phil. Trans. R. Soc. B (2011)Increasing evidence suggests that TGFb can signal
independently of Smad function [67]. For instance,
TGFb type I receptor can phosphorylate both
serine and tyrosine residues in the SHCA adaptor,
recruiting adaptor protein GRB2 and the Ras guanine
exchange factor (GEF) son of sevenless (SOS) to acti-
vate Ras-Raf-MEK-ERK mitogen-activated protein
(MAP) kinase in mammalian cells [81]. The tyrosine
kinase Src can phosphorylate the cytoplasmic
domain of the TGFbRII leading to GRB2 and SHC
recruitment enabling the activation of the p38 MAP
kinase pathway [82]. Moreover the JNK MAP kinase
and Rho kinase signalling pathways can be activated
by TGFb [83]. In the context of lens fibrosis, Smad-
independent signalling pathways ERK and p38 MAP
kinase are activated by TGFb in human lens epithelial
cells [6]. The notion that TGFb-induced matrix
contraction by human lens epithelial cells is mediated
by Smad-independent signalling [6] is supported by
investigations in non-ocular systems where Rho/Rho
kinase [84], ERK [85] and p38 MAPK [86] promote
matrix contraction. Moreover, the ERK signalling
pathways can promote matrix contraction by activation
of myosin light chain kinase, a key enzymatic regulator
of contractile force [85]. Therefore, with respect to
lens fibrosis, the role of Smad-independent signalling
pathways in TGFb-induced matrix contraction needs
further investigation to underpin the regulatory
TGFb mechanism controlling this detrimental fibrotic
characteristic.
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Figure 8. aSMA is not critical for TGFb-induced matrix contraction: 24 h patch assay analysis. FHL 124 cells were seeded to
form patches, then transfected with siRNA targeted to aSMA (thus reducing aSMA expression) or a scrambled (SCR) nega-
tive control and maintained in EMEM supplemented with 2%FCS. Patches were measured after 24 h of culture in control
conditions or exposed to 10 ngml21 (a) TGFb1 or (b) TGFb2. Data represent the mean+SEM (n ¼ 4). *Significant differ-
ence between treated and untreated siaSMA (p  0.05, ANOVA with the Tukey test); psignificant difference between
siaSMA þTGFb treated groups and siSCR þTGFb-treated groups (p  0.05, ANOVA with the Tukey test).
(c) Representative images of dishes for each experimental group ((a) open bar, 2TGFb1; filled black bar, þTGFb1, (b)
open bar, 2TGFb2; filled black bar, þTGFb2). Data previously published by Dawes et al. [5] with permission from the copy-
right holder, the Association for Research in Vision and Ophthalmology (ARVO).
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independent pathways can mediate fibrotic events
throughout the body. The production of the ECM
protein fibronectin is dependent on TGFb–p38 MAP
kinase signalling in human proximal tubular epithelial
cells [87] and TGFb–JNK MAP kinase signalling in a
human fibrosarcoma cell line [88]. Moreover, TGFb
Smad-independent MEK/ERK MAP kinase pathway
has been implicated in the pathogenesis of scleroderma
[89] and Rho kinase inhibitors have been shown to
diminish fibrosis, detected by reduced presence of
transdifferentiation markers and ECM proteins, in
experimental models of vascular fibrosis and renal
damage [90–92]. Most interestingly, there is evidence
of cross talk between the Smad and MAP kinase path-
ways in experimental models of fibrosis. For example,
TGFb-induced angiotensin receptor expression in pul-
monary fibrosis [93] and aSMA expression in renal
proximal tubular cells [87] involve Smad-dependent
and -independent MAP kinase signalling pathways.
The rationale for cross talk between TGFb signallingPhil. Trans. R. Soc. B (2011)pathways is based on theMAPkinase cascademodifying
Smad activity by targeting phosphorylation sites in the
linker regions of Smad3 and Smad4 [94].
The Wnt signalling pathway has also been implica-
ted in fibrotic disorders and is reported to play a key
role in TGFb-induced transdifferentiation [95–98].
The canonicalWnt signallingpathway regulatesb-catenin
activity. Wnt ligand binding to receptors (Frizzled) and
co-receptor low-density lipoprotein receptor-related
protein (LRP) leads to the phosphorylation of LRP6,
by glycogen synthase kinase-3b (GSK-3b) and casein
kinase g, in its cytoplasmic region. This leads to the
recruitment of cytosolic proteins, dishevelled and axin
[96]. As a result of the association of GSK-3b with
Frizzled receptors and LRP, b-catenin phosphorylation
is reduced. In this form, b-catenin is no longer targeted
for degradation and consequently accumulates in the
cytoplasm before translocating to the nucleus where
it associates with DNA binding factors Terhorst T cell
factor (TCF) and lymphocyte enhancer factor
(LEF) to regulate gene expression [96]. TGFb is believed
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Figure 9. Putative pathways relating TGFb to fibrotic events, (a) based on conventional dogma and (b) incorporating novel
findings that challenge this view. Coll, collagen; FN, fibronectin.
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and Smad-independent mechanisms. Smad-mediated
signalling can activate integrin like kinase, which leads
toGSKandAkt phosphorylation; this results inb-catenin
nuclear translocation [98]. Smad-independent Akt
phosphorylation can also suppress GSK activity and pro-
moteb-catenin translocation [98]. In both cases the result
is topromote transdifferentiation.A report usingwhole rat
lens cultures exposed toTGFb2 and transgenicmice over
expressing TGFb1 demonstrated increased level of Wnt
ligands and Frizzled receptors compared with controls;
moreover, this was associated with increased accumu-
lation of b-catenin in the nucleus of cataract forming
cells and expression of aSMA/plaque formation [99].Phil. Trans. R. Soc. B (2011)It is therefore of great importance for future research
in lens fibrosis to focus on disseminating the importance
of both Smad-independent and Smad-dependent path-
ways and the interactions between them in the cellular
events that give rise to fibrosis. The knowledge gained
will aid the development of therapeutic drugs to prevent
ASC and PCO formation.6. EXTRACELLULAR MATRIX PRODUCTION AND
DEPOSITION
The ECM, once believed to be a static structure,
acting as a scaffold to maintain tissue integrity, regu-
lates many aspects of cell function including growth,
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ECM by increased synthesis and deposition of ECM
proteins is fundamental to the pathogenesis of fibrotic
pathologies [1]. Lens epithelial cells and lens fibres are
associated with a basement membrane termed the lens
capsule, which is predominantly composed of collagen
IV, along with laminin, heparin sulphate proteoglycans
and tenascin [100]. These ECM components maintain
the structural integrity of the lens capsule, enabling
lens cell attachment and migration. During the patho-
genesis of ASC and PCO, lens cells aberrantly
synthesize and deposit new ECM components that
contribute to the formation of fibrotic plaques and
light scattering regions; the deposited components
include fibronectin, vitronectin and collagen types I
and III [101]. These ECM proteins are commonly
associated with fibrosis and wound healing in many
systems throughout the body. For example in patients
with scleroderma, an abnormal accumulation of col-
lagens I and III is the most prominent pathological
manifestation of the disease in the skin [102]. The
excessive accumulation of ECM constituents on the
basement membrane of the lens capsule can influence
cell behaviour and in particular EMT and cell
migration, thus promoting fibrotic pathologies.
The ECM constituents vitronectin and fibronectin
have been investigated in PCO-related events [103].
It has also been reported that cells from explant
cultures adhere and migrate on vitronectin and fibro-
nectin matrices, which was associated with increased
aSMA staining and a more elongated/fibroblast-like
cell appearance [103]. Most interestingly, the ED-A
domain of fibronectin has been proposed to be crucial
for the induction of aSMA expression [104]; appli-
cation of an inhibiting RGD peptide to corneal
fibroblasts, preventing the interaction of fibronectin
and its integrin receptor, suppressed aSMA
expression. Therefore, fibronectin expression may be
of importance to the transdifferentiation events that
occur during lens fibrosis. Furthermore, investigations
by Saika et al. [105] identified the expression of the
proteoglycan lumican in post-mortem capsular bag
specimens. Additional investigations employing lumi-
can knockout mice revealed that following trauma by
a needle puncture injury of the anterior lens capsule,
there was a delay in aSMA expression and appearance
of transdifferentiated cells [105]. These studies are
consistent with the notion that modifications in
ECM constituents influencing lens cell behaviour
enable the development of fibrotic pathologies. Similar
modifications to the basement membrane and sub-
sequent changes to cell behaviour are observed
during the development of liver fibrosis [106]. HSCs
are affected by ECM content; in the normal liver
quiescent HSCs are surrounded by a basement
membrane-like matrix [107]. In response to injury
the composition of the ECM changes towards fibrillar
collagen which promotes HSCs to transdifferentiate.
Secreted protein acidic and rich in cysteine
(SPARC) may play a role in wound healing, tumour
progression and cell proliferation by influencing the
expression of ECM proteins [108]. Modifications of
SPARC expression have particular relevance to lens
fibrosis. SPARC-null mice have been shown to developPhil. Trans. R. Soc. B (2011)cataracts by 3-4 months of age due to disruptions in
lens cell growth [109]. Investigations comparing lens
cells derived from wild-type mice and SPARC knock-
out mice show SPARC expression to decrease
laminin deposition [110]. A follow-on study also
tested the effects of TGFb in lens cells from wild-
type and SPARC null mice [111]. Interestingly,
TGFb-induced expression of both fibronectin and
aSMA was evident in both groups, but the greatest
level observed was in the SPARC null group,
suggesting that SPARC can suppress to some degree
TGFb-induced transdifferentiation. In addition, dexa-
methasone-increased SPARC expression of lens cells
was shown to correlate with a reduced level of fibro-
nectin and collagen type IV, therefore suggesting
SPARC may modulate the lens ECM to suppress
transdifferentiation events; thus, maintaining high
levels of SPARC expression following cataract surgery
may be of benefit in the prevention of PCO. However,
with respect to other fibrotic pathologies increasing
SPARC expression may be counter-productive as
collagen accumulation is shown to be decreased in
SPARC null mice with bleomycin-induced pulmonary
fibrosis and SPARC expression is induced following
lung injury, implicating SPARC in the development
of pulmonary fibrosis [112].
Matrix components play an important role in the
function of growth factors. FGF and hepatocyte growth
factor (HGF), for example, require heparin binding to
facilitate interaction with their corresponding receptor;
therefore, distribution of heparin sulphate proteoglycans
in association with the lens capsule matrix could play
a critical role in FGF and HGF mediated events [113–
115]. Growth factors such as FGF can exacerbate the
effects of TGFb [116], which is also known to bind
to several matrix components including decorin and col-
lagen type IV [117]. As the level of many growth factors
are elevated following surgery, the accumulation of these
proteins in association with the capsule is likely to
increase accordingly [33,118]. Slow release resulting
from proteolytic cleavage of this reservoir of potential
modulators of cell function is therefore likely to influence
fibrotic progression for significant periods.7. PROTEOLYTIC REGULATION OF THE
EXTRACELLULAR MATRIX
Proteases are a group of endogenous enzymes that
through the process of proteolysis hydrolyse peptide
bonds of proteins. Matrix metalloproteinases (MMPs),
calpains, cathepsins the ubiquitin–proteosome pathway
and caspases are just a small number of the different
types of proteases that can contribute to development
and disease [119]. For the purpose of this current
review we will concentrate on the role of MMPs, which
are commonly implicated in many fibrotic disorders.
The MMPs belong to the larger family of proteases
known as the metzincin superfamily. There are 26
MMPs including six membrane tethered (MT)-
MMPs in addition to four natural MMP inhibitors,
the tissue inhibitors of MMPs (TIMPs). The MMP
and TIMP family members can act on multiple targets
and perform a variety of functions which maintain and
remodel tissue architecture [120].
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Figure 10. Detection of MMP-2 and -9 in culture media of
(a) in vitro capsular bags and (b) cultured ex vivo specimens,
by gelatin zymography. Analysis of in vitro capsular bags was
performed on the media of three cultures. Data are represen-
tative of the pattern observed in all cases in each group. In
the case of cultured ex vivo specimens, the medium from
one additional culture was analysed and showed a profile
similar to the presented data. Data previously published by
Wormstone et al. [17] with permission from the copyright
holder, the Association for Research in Vision and
Ophthalmology (ARVO).
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pathological disorders despite the fundamental func-
tions MMPs maintain in normal biological processes
such as embryogenesis, the creation of space in order
for cells to migrate, and regulation of intracellular con-
nection and signalling cascades [121]. However, the
involvement of MMPs in disease cannot be ignored
and their direct correlation in conditions such as
arthritis, cancer, nephritis and importantly fibrosis
has been significantly documented. The involvement
of MMPs in fibrosis seems counterintuitive as the
primary role of MMPs is to breakdown matrix and
fibrosis is essentially an accrual of copious ECM.
However alternative functions for MMPs include the
ability to release growth factors and cytokines such
as FGF-2 and TGFb from supporting matrix and acti-
vation of macrophages that have direct roles in fibrosis
development [58,122,123].
Numerous fibrotic diseases have MMP involve-
ment. Models for ischaemic injury in normal rat
kidney cells have shown that MT1-MMP causes
E-cadherin cleavage and a decrease in N-cadherin
level; this results in a loss of epithelial cells in the prox-
imal tubules [124]. Ischaemic attack is the principal
cause of acute renal failure, leaving only the basement
membrane for filtration yielding filtrate return and
tubular obstruction. MT1-MMP (MMP-14) is a
MT-MMP that is involved in the activation of pro-
form MMP-2; increased MMP-2 expression is crucial
in the development of chronic kidney disease. In a
transgenic mouse model, over-expression of MMP-2
in renal proximal tubular cells transformed the
basement membrane instigating tubular EMT with
resultant tubular atrophy, fibrosis and renal failure
[125]. This study indicated that MMP-2 alone
without wounding was enough to induce glomerulo-
sclerosis, interstitial fibrosis, tubular atrophy and
renal failure.
MMPs have also been implicated in complications
of the lens. Studies by Dwivedi et al. [126] demon-
strated that both TGFb and MMPs play important
roles in the formation of ASC plaques. Whole rat
lenses cultured in the presence of TGFb2 alone devel-
oped numerous distinct opacities on the anterior
surface of the lens that contained aSMA expression
and multilayering of cells [126]. Co-treatment of
lenses with TGFb2 and the broad-spectrum MMP
inhibitor GM6001 prevented the formation of
TGFb2-mediated opacities, abrogated the expression
of aSMA and inhibited cellular multilayering [126].
Furthermore, analysis of conditioned media from the
whole lens cultures showed that pro-form and active
MMP-2 was initiated by the presence of TGFb2; the
pro-form of MMP-9 was also elevated along with frag-
mented E-cadherin. These changes were attenuated by
MMP inhibitors [126]. As observed in rat ASC in vitro
models, TGFb2 also augments the level of both
MMP-2 and -9 in the media of in vitro human capsular
bag cultures (figure 10) [17]; importantly, bothMMP-2
and -9 are able to degrade collagen type IV [127], the
main constituent of the lens capsule. Neutralization of
TGFb2 with CAT-152 (a human monoclonal anti-
TGFb2 antibody) prevented these TGFb2-induced
events [17]. Interestingly, bathing media obtainedPhil. Trans. R. Soc. B (2011)from culture of ex vivo capsular bags (donor lenses
from patients who have previously had cataract oper-
ations) in serum-free media also revealed expression
of MMP-2 and -9, indicating that ex vivo capsular
bags secrete MMPs in a manner similar to TGFb2
-treated cultures (figure 10) [17].
Furthermore, Wong et al. [128] found that released
MMP-2 and -9 following sham cataract operations on
human lenses was inhibited by application of 100 mM
Ilomostat (a broad-specrum MMP inhibitor). Ilomo-
stat significantly reduced cell migration and capsular
bag wrinkling. Additionally, radiolabel binding analysis
demonstrates that the lens capsule is a store for TGFb2
[33] along with FGF [123], and insulin-like growth
factor [122,129]. As MMPs can function to release
growth factors from the ECM it is reasonable to suggest
that sustained levels can increase the concentration of
cytokines available to lens cells over extended periods.
This could therefore act as a link between short-term
inflammation and progressive lens fibrosis.8. EXTRACELLULAR MATRIX/CELL
COMMUNICATION—INTEGRINS
The interaction of the ECM with the cell environment
is mediated by a group of distinct cell surface receptors
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units. The interaction of specific integrins with their
respective ECM ligands enables cells to adhere to and
migrate across the ECM [130]. Moreover, integrins
function as cell signalling centres, transducing signals
to and from the microenvironment [130]; therefore,
any altered regulation of integrin expression or function
can promote the development of fibrotic disease.
With respect to the lens,Dawes et al. [30] performed a
microarray analysis of the human lens epithelial cell line
FHL124 to determine those integrins that are expressed
in the human lens and identify those of potential impor-
tance to the formation of fibrotic lens pathologies
(figure 11). This study revealed that the integrin b1,
b2, b3, b5 and b6 subunits are expressed by human
lens epithelial cells, with the integrin b1 subunit being
the most abundantly expressed. b1 integrin is the most
diverse integrin subunit as it can associate with 12 differ-
ent a integrin chains [131], thus is the most widely
expressed integrin in numerous cell types throughout
the body [131]. With respect to the alpha sub-units
expressed by human lens epithelial cells, a1, a2, a3,
a4, a5, a6, a7, a10, a11, aE, aM and aV have been
detected [30]. Treatment of human lens epithelial cells
with the profibrotic cytokine TGFb notably increased
the expression of a5, a11, aVand b5 integrin subunits.
Of particular interest to ASC and PCO develop-
ment is the expression of a5b1 integrin, which along
with its matrix ligand fibronectin is significantly upre-
gulated by TGFb in both the human capsular bag and
lens epithelial cell line [5,30]. The interaction between
a5b1 integrin and fibronectin can regulate the
expression of aSMA and transdifferentiation of cor-
neal fibroblast cells to myofibroblasts [132].
Moreover, it has been proposed that a5b1 integrin
and fibronectin form a putative contractile apparatus
with aSMA [132,133]. A recent study has investigated
the putative role of fibronectin/fibronectin receptor
interaction in relation to TGFb-induced matrix
contraction by human lens epithelial cells [5]; appli-
cation of an RGDS peptide to block the RGD
binding site of a5 integrin revealed that the fibronec-
tin/fibronectin receptor interaction was not required
to promote matrix contraction by TGFb [5]. In
addition, Marcantonio et al. [134] demonstrated that
a5b1 integrin expression was altered in FHL 124
cells following TGFb exposure, such that a diffuse
pattern across the cell was observed, with membrane
bound a5b1 integrin having no association with
actin filaments. The aforementioned investigations
therefore suggest that in the human lens the distri-
bution of a5b1 integrin in response to TGFb could
provide multiple sites of attachment to the underlying
matrix to negatively regulate matrix contraction.
Abnormal expression of a5b1 integrin plays an impor-
tant role in the pathogenesis of fibrosis throughout the
body. An upregulation in a5b1 integrin expression has
been detected in pulmonary tissue sections from
patients with idiopathic pulmonary fibrosis [135] and
in interstitial fibroblasts in progressive renal fibrosis
[136]. In non-ocular systems the importance of the
role of integrins in mediating matrix fibrotic events
has been widely investigated. With respect to the regu-
lation of matrix contraction in the pathogenesis ofPhil. Trans. R. Soc. B (2011)fibrosis, it has been suggested that contraction of col-
lagen gels by renal fibroblasts is dependent on b1
integrin [137]; moreover, a1 integrin deficient mice
develop severe glomerulosclerosis [138]. The regu-
lation of matrix contraction by the collagen receptors
a1b1 integrin along with a2b1 integrin in fibrotic
disease remains an intriguing possibility and an inter-
esting area for future investigation with respect to
ASC and PCO.
The integrin aVb5 is of importance in the for-
mation of fibrotic pathologies due to its role in
enabling the mechanotransduction of signals from
extracellular microenvironments that influence cell
behaviour [139]. With respect to fibrosis, aVb5 integ-
rin is of importance in the transdifferentiation of cells
to myofibroblasts [140]. Moreover, aVb5 integrin
mediates the release of TGFb from lung myofibro-
blasts undergoing contraction [141]. The expression
of aVb5 integrin is upregulated in scleroderma fibro-
blasts [142] and interstitial renal fibroblasts [136].
With respect to the lens, TGFb treatment of lens epi-
thelial cells promotes aVb5 expression [30] and is a
potent inducer of transdifferentiation of lens epithelial
cells to myofibroblasts [5,17]. These investigations
have led to speculation over the bidirectional role of
aVb5 integrin in the formation of lens fibrosis [143],
which could occur through (i) mediating transdifferen-
tiation induced by increasing levels of active TGFb
that result from trauma to the lens or (ii) mediating
signals from myofibroblasts back to the ECM that acti-
vate matrix-associated TGFb. Injury by mechanical
trauma can modulate integrin expression, which has
particular relevance to fibrotic conditions that occur
following surgery such as PCO. An interesting study
was carried out by Sponer et al. [144] using the
human capsular bag system which demonstrated that
aVb6 integrin is increased in capsular bags cultured
in protein-free medium compared with cultured
intact lenses. Similarly, in non-ocular fibrotic diseases
aVb6 integrin is increased following acute biliary
injury [145]. aVb6 integrin activates TGFb through
its association with an RGD peptide in the latency
associated peptide [146]; the importance of aVb6
integrin to TGFb activation in fibrotic disease was
confirmed in b6 null mice which fail to develop a
fibrotic response following biliary injury [145]. There-
fore, integrin aVb6 and aVb5 may have essential
roles in sustaining TGFb activation, thus enabling
the initiation of fibrotic events that follow localized
tissue injury to both the lens and throughout the
rest of the body.
Weaver et al. [147] have shown that integrin linked
kinase (ILK), a serine threonine kinase that binds to
the cytoplasmic tail of b1, 2 and 3 integrin subunits
is present in both mouse and human lens cells. ILK
is a multidomain focal adhesion protein that is an
important regulator of both ECM adhesion and
signal transduction. Studies suggest ILK to be an
important mediator of EMT [11,147,148]; for
instance, ILK expression of cultured mouse and
human lens cells correlates with increased levels of
transdifferentiation markers fibronectin and aSMA.
Moreover, transfection of lens epithelial cells with
ILK-expressing constructs induces a morphological
(a)
(b)
Figure 11. A gene expression profile of integrins in FHL 124 cells. (a) The baseline signal of integrin gene expression detected
in non-stimulated serum-free controls using oligonucleotide microarrays. (b) Changes detected in gene expression of integrins
following 24 hr culture in TGFb (10 ngml21) conditions using oligonucleotide microarrays. The data are presented in a
colorimetric form to indicate (a) level detected and (b) fold change. Data previously published by Dawes et al. [30] with
permission from Molecular Vision.
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ILK in mediating EMT in renal fibrosis has been pro-
posed [148]. Interestingly, ILKhas been reported to co-
localize with a5b1 integrin, which was enhanced by the
presence of fibronectin [147]. Therefore, the role of
ILK in regulating EMT via interaction with fibronec-
tin–a5b1 integrin remains an interesting area of study
with respect to the pathogenesis of fibrosis.9. SUMMARY
Fibrotic disorders of the lens affect millions. The
unique biological properties of the lens allow it to
serve as an exquisite biological tool to investigate the
processes that underpin fibrosis. Employing the lens
as a study system, we can observe hyperproliferation
following injury, matrix production/deposition, matrix
contraction and transdifferentiation to myofibroblasts.
Using a variety of strategies employing cell lines, trans-
genic animals and tissue culture models, a number of
pathways driving lens fibrosis are starting to emerge.
The lens is therefore an excellent experimental model
system to investigate tissue fibrosis per se.
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